MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Amgen.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Amgen.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Amgen.com most likely does not offer any adult content.
Audience
-
Bounce rate
-
Time on site
02:26
AVG
-
Gender
Men
44%
Women
56%
Popular pages
-
Finding Balance: As we celebrate Mother’s Day, several female leaders share how Amgen fosters an
Amgen recognizes one of the most important roles outside of the workplace. Happy Mother’s Day.
-
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the ant...
-
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC
traindications Prolia® is contraindicated in patients with hypocalcemia. Preâexisting hypocalcemia must be corrected prior to initiating Prolia®. Prolia® is contraindicated in womenÂ...
-
Taking on Vasculitis, Together: Meet Rodney and Debbie | Amgen
To gain a deeper understanding of their journey with ANCA-associated vasculitis (AAV), Amgen recently sat down with Rodney and Debbie to hear their story and what advice they have for others.
-
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022| Amgen
AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks ...
-
Amgen | A Worldwide Pioneer in Biotechnology
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.